Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria

• Published in: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology Vol. 12; no. 5; p. e557
• Main Authors: Kraak, Robin P, Grundeken, Maik J, Hassell, Mariëlla E, Elias, Joëlle, Koch, Karel T, Henriques, José P, Piek, Jan J, Baan, Jr, Jan, Vis, Marije M, Tijssen, Jan G P, de Winter, Robbert J, Wykrzykowska, Joanna J
• Format: Journal Article
• Language: English
• Published: France 01.08.2016
• Subjects: Absorbable Implants - adverse effects; Adult; Aged; Cardiovascular Agents - administration & dosage; Coronary Angiography - methods; Coronary Artery Disease - therapy; Drug-Eluting Stents - adverse effects; Female; Humans; Male; Middle Aged; Myocardial Infarction - etiology; Myocardial Infarction - therapy; Percutaneous Coronary Intervention - methods; Prosthesis Design; Registries; Sirolimus - administration & dosage; Treatment Outcome
• ISSN: 1969-6213
• DOI: 10.4244/eijv12i5a95

This study presents the two-year clinical outcomes of the Amsterdam ABSORB registry stratified by lesion and patient characteristics complexity (SYNTAX score and ABSORB II study enrolment criteria). Patients treated with BVS were included in this prospective registry and stratified according to the ABSORB II trial inclusion and exclusion criteria and the SYNTAX score. The registry comprises 135 patients (59±11 years, 73% male, 18% diabetic) with 159 lesions. Median follow-up duration was 774 days (742-829). Median SYNTAX score was 11.5 (Q1-Q3: 6-17.5). Two-year event rates were cardiac death 0.7%, MI 5.3%, TVR 13.6%, TLR 11.4%, definite ST 3.0% and TVF 14.4%, respectively. Stratified analyses showed a significantly higher revascularisation rate in patients not meeting ABSORB II criteria (TVR: 2.3% vs. 19.2%, p=0.010, and TLR: 2.3% vs. 15.8%, p=0.025) and patients with SYNTAX score ≥11.5 (TVR: 4.8% vs. 21.8%, p=0.006, and TLR: 3.2% vs. 17.4%, p=0.007). The use of Absorb BVS in patients meeting the ABSORB II trial inclusion criteria or those with low SYNTAX scores is associated with acceptable clinical outcomes at two-year follow-up. Patients with more complex characteristics have significantly higher revascularisation rates.